The U.S. Food and Drug Administration rejected ImClone 's original application in December 2001 , saying the trial had been sloppily conducted .
The Food and Drug Administration ultimately denied ImClone 's drug application in December 2001 , saying that an Erbitux clinical trial was deficient .